Two separate experimental immune models suggest that EpiCor may help modulate multiple acute and potentially chronic immunologic and inflammatory control mechanisms.
Researchers at KGK Synergize of Canada and Embria Health Sciences, maker of EpiCor, noticed significant differences in inflammation in both rats and mice used in the studies. The results also reaffirmed five other human clinical studies that showed EpiCor might address cold, flu and allergy symptoms.
All of these studies suggest the same thing: EpiCor may be efficacious in several areas of immune support, said Larry E. Robinson, Ph.D., vice president of scientific affairs for Embria Health Sciences. The strength of these results is further evidence of EpiCor’s immune-balancing ability. The research analysis can be found here.